skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Synthetic heparin-binding factor analogs

Abstract

The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain, and preferably two peptide chains branched from a dipeptide branch moiety composed of two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a linker, which may be a hydrophobic linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.

Inventors:
 [1];  [2];  [3];  [4]
  1. Poquott, NY
  2. Gaithersburg, MD
  3. Plainview, NY
  4. Shoreham, NY
Issue Date:
Research Org.:
Brookhaven National Lab. (BNL), Upton, NY (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
989000
Patent Number(s):
7700563
Application Number:
7,700,563
Assignee:
BioSurface Engineering Technologies, Inc. (Rockville, MD); Brookhaven Science Associates (Upton, NY)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
DOE Contract Number:  
AC02-98CH10886
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY

Citation Formats

Pena, Louis A, Zamora, Paul O, Lin, Xinhua, and Glass, John D. Synthetic heparin-binding factor analogs. United States: N. p., 2010. Web.
Pena, Louis A, Zamora, Paul O, Lin, Xinhua, & Glass, John D. Synthetic heparin-binding factor analogs. United States.
Pena, Louis A, Zamora, Paul O, Lin, Xinhua, and Glass, John D. Tue . "Synthetic heparin-binding factor analogs". United States. https://www.osti.gov/servlets/purl/989000.
@article{osti_989000,
title = {Synthetic heparin-binding factor analogs},
author = {Pena, Louis A and Zamora, Paul O and Lin, Xinhua and Glass, John D},
abstractNote = {The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain, and preferably two peptide chains branched from a dipeptide branch moiety composed of two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a linker, which may be a hydrophobic linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2010},
month = {4}
}

Patent:

Save / Share:

Works referenced in this record:

RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization
journal, December 2003


Role of heparan sulfate in fibroblast growth factor signalling: a structural view
journal, September 2001


Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope
journal, September 2003


Influence of BMPs on the Formation of Osteoblastic Lesions in Metastatic Prostate Cancer
journal, August 2005


Novel Branching Membrane Translocational Peptide as Gene Delivery Vector
journal, November 2002


Receptor- and heparin-binding domains of basic fibroblast growth factor.
journal, April 1988


A heparin binding synthetic peptide from human HIP / RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin
journal, February 2003


Hydroxyapatite Granule Graft Combined With Recombinant Human Bone Morphogenic Protein-2 for Solid Lumbar Fusion
journal, January 2002


Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin.
journal, December 1981


Powers and Pitfalls in Sequence Analysis: The 70% Hurdle
journal, April 2000


Semirational design of a potent, artificial agonist of fibroblast growth factor receptors
journal, December 1999

  • Ballinger, Marcus D.; Shyamala, Venkatakrishna; Forrest, Louise D.
  • Nature Biotechnology, Vol. 17, Issue 12, p. 1199-1204
  • https://doi.org/10.1038/70746

Errors in genome annotation
journal, April 1999


Local Delivery of Basic Fibroblast Growth Factor (bFGF) Using Adsorbed Silyl-heparin, Benzyl-bis(dimethylsilylmethyl)oxycarbamoyl-heparin
journal, September 2002


A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein
journal, June 1998


Enhanced osteogenic promotion around dental implants with synthetic binding motif mimicking bone morphogenetic protein (BMP)-2
journal, January 2006


Evaluation of Carriers of Bone Morphogenetic Protein for Spinal Fusion
journal, January 2001


Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox
book, January 1994


The challenges of genome sequence annotation or “The devil is in the details”
journal, November 1997


Growing better blood vessels
journal, November 2001


Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans
journal, March 2000


Synthesis of Native Proteins by Chemical Ligation
journal, June 2000


Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells.
journal, January 1991


Protein annotation: detective work for function prediction
journal, June 1998


Time for treating bone fracture using rhBMP-2: A randomised placebo controlled mouse fracture trial
journal, May 2005


Engineering of an FGF–proteoglycan fusion protein with heparin-independent, mitogenic activity
journal, June 2000


From genes to protein structure and function: novel applications of computational approaches in the genomic era
journal, January 2000


Growth factor delivery for bone tissue repair: an update
journal, November 2004


BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II
journal, July 2000


Tandem Ligation of Multipartite Peptides with Cell-Permeable Activity
journal, January 2003


Go hunting in sequence databases but watch out for the traps
journal, October 1996


BMP signaling components are expressed in human fracture callus
journal, September 2003


Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice
journal, July 2001


Designing Biomaterials to Direct Biological Responses
journal, June 1999


Polymeric system for dual growth factor delivery
journal, November 2001


αvβ3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells
journal, December 1997


A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells
journal, June 1997


Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis
journal, April 2000


Additivity of mutational effects in proteins
journal, September 1990


Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide
journal, January 2004